The Taiwan Chip-based Industrial Innovation Program (Taiwan CbI) is a collaborative effort by various Taiwanese government ministries, leveraging Taiwan’s semiconductor expertise by integrating chips with key innovations. Startups should be focused on IC design innovations and Chip-based innovative applications in the following industries: data & security, mobility, sustainability, manufacturing and medtech.
Leading critical environment air quality management company looks for startups in two applications to address market needs resulting from COVID-19.
1. Airborne particulate matter counting and identification
2. New Air Disinfection and Monitoring Technology
P&G is looking for new approaches and technologies that can help them to address key business challenges/opportunities.
The 2024 MIT Health Science Technology Conference will highlight broad and transformative trends in biology and healthcare, including early-stage discovery, immune cell responses, diagnostics, clinical capabilities, process development, rapid and continuous manufacturing, robotics and automation, and sustainability, all enhanced by artificial intelligence and machine learning technologies. Leading MIT researchers and MIT-connected startups will showcase these advances and discuss their implications for improving human health.
Early-stage startups are invited to MIT.nano to learn more about the START.nano program and explore how its state-of-the-art laboratories can support their growth.
Anurag Bajpayee, Founder and CEO, Gradiant
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.